The biological activity of cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Study identifier:D8480C00046
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label, Phase II Study to Evaluate the Biological Activity of cediranib (AZD2171) as Measured by [F 18] fluoro 2 deoxy D glucose - Positron Emission Tomography (FDG-PET) Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate
Medical condition
Gastrointestinal Stromal Tumors
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD2171
Sex
All
Actual Enrollment
35
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2006
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Dec 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Jane Robertson
AstraZeneca
